EmilyGRobinsonMD

Oncology • Janesville, WI

Hematologic Oncology

Physician

Join to view full profile

Dr. Robinson is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Robinson's full profile

Already have an account?

Office
1000 Mineral Point Ave
Janesville, WI 53548
Phone+1 608-756-6871
Is this information wrong?

Summary

Dr. Emily Robinson is an oncologist in Janesville, WI and is affiliated with multiple hospitals in the area, including Mercyhealth Hospital and Trauma Center - Janesville and Mercyhealth Hospital and Medical Center - Walworth. She received her medical degree from University of Wisconsin School of Medicine and Public Health and has been in practice 26 years. She specializes in hematologic oncology and is experienced in seminoma, adenocarcinoma of the prostate, hereditary breast/ovarian cancer, hereditary prostate cancer, and infection-induced thrombocytopenia.

Education & Training

Wake Forest University Baptist Medical CenterFellowship, Hematology and Medical Oncology, 1994 - 1996
Wake Forest University School of MedicineResidency, Internal Medicine, 1991 - 1994
University of Wisconsin School of Medicine & Public HealthClass of 1991

Certifications & Licensure

WI State Medical License 1996 - 2025
NC State Medical License 1993 - 1998
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012

Clinical Trials

Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy Start of enrollment: 2008 Nov 10
Active, not recruiting
Phase 3
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia Start of enrollment: 2009 Jan 29
Active, not recruiting
Phase 3
S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer Start of enrollment: 2011 Nov 01
Completed
Not Applicable
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Start of enrollment: 2011 Jan 15
Active, not recruiting
Phase 3
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Start of enrollment: 2011 Jan 06
Active, not recruiting
Phase 3
S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer Start of enrollment: 2013 Sep 12
Active, not recruiting
Phase 3
S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer Start of enrollment: 2013 Mar 08
Active, not recruiting
Phase 3
A Brief Patient-Controlled Intervention for a Symptom Cluster in Advanced Cancer Start of enrollment: 2013 Dec 01
Completed
Not Applicable
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer Start of enrollment: 2015 Jul 26
Recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

Reply to The effects of curative-intent cancer therapy on employment, work ability, and work limitations
Amye J. Tevaarwerk, Kris Kwekkeboom, Kevin A. Buhr, Alexandra Dennee, William Conkright, Adedayo A. Onitilo, Emily Robinson, Harish Ahuja, Roger W. Kwong, Ranveer Nana...> ;Cancer. 2021 Aug 15
8 citations
Results from a prospective longitudinal survey of employment and work outcomes in newly diagnosed cancer patients during and after curative-intent chemotherapy: A Wisc...
Amye J. Tevaarwerk, Kris Kwekkeboom, Kevin A. Buhr, Alexandra Dennee, William Conkright, Adedayo A. Onitilo, Emily Robinson, Harish Ahuja, Roger W. Kwong, Ranveer Nana...> ;Cancer. 2021 Mar 1
29 citations
Vorinostat and bortezomib as third-line therapy in patients with advanced non-small cell lung cancer: a Wisconsin Oncology Network Phase II study
Tien Hoang, Toby C. Campbell, Chong Zhang, KyungMann Kim, Jill M. Kolesar, Kurt R. Oettel, Jules H. Blank, Emily Robinson, Harish Ahuja, Ron J. Kirschling, Peter H. Jo...> ;Investigational New Drugs. 2014 Feb 1
10 citations
A phase I study of sorafenib, oxaliplatin and 2 days of high dose capecitabine in advanced pancreatic and biliary tract cancer: a Wisconsin oncology network study.
Noelle K. LoConte, Kyle D. Holen, William R. Schelman, Daniel Mulkerin, Dustin A. Deming, Hilary R. Hernan, Anne M. Traynor, Timothy Goggins, David Groteluschen, Kurt ...> ;Investigational New Drugs. 2013 Aug 1
Vorinostat (V) and bortezomib (B) as third-line treatment in patients with advanced non-small cell lung cancer (NSCLC): A Wisconsin Oncology Network Phase II Study.
Jones MW, Zhang C, Oettel KR, Blank JH, Robinson EG, Ahuja HG, Kirschling RJ, Johnson PH, Huie MS, Kolesar J, Wims MB, Hernan H, Campbell TC, Traynor AM, Hoang T> ;J. Clin. Oncol.. 2011-05-20
41 citations
Phase II trial of perillyl alcohol (NSC 641066) administered daily in patients with metastatic androgen independent prostate cancer.
Glenn Liu, Kurt R. Oettel, Howard H. Bailey, Lynn Van Ummersen, Kendra D. Tutsch, Mary Jane Staab, Dorothea Horvath, Dona Alberti, Rhoda Z. Arzoomanian, Hamied Rezazad...> ;Investigational New Drugs. 2003 Aug 1
Join now to see all

Press Mentions

'Not Only for Older People': Colon Cancer Rates Rising Among 50 and YoungerMarch 28th, 2022

Professional Memberships

American College of Physicians - ACP
Member

Hospital Affiliations

Mercyhealth Hospital and Trauma Center - JanesvilleJanesville, Wisconsin
Mercyhealth Hospital and Medical Center - WalworthLake Geneva, Wisconsin